Loading stock data…
VRTX
$477.36+4.27 (+0.90%)
Market ClosedLast close Jul 24
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vertex Pharmaceuticals Incorporated in the Healthcare sector is trading at $477.36 with a market capitalization of $114.3B. Wall Street consensus targets $554.91 (23 analysts), implying a +16.2% move over the next 12 months. The stock is currently 11% below its 52-week high of $533.67, remaining 5.8% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 19 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +16.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 19) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.99B↓ | $3.19B↑ | $3.08B↑ | $2.96B↑ | $2.77B |
| Gross Profit | $2.59B↓ | $2.72B↑ | $2.66B↑ | $2.56B↑ | $2.41B |
| Operating Income | $1.14B↑ | $1.13B↓ | $1.24B↑ | $1.15B↑ | $1.03B |
| Net Income | $1.03B↓ | $1.19B↑ | $1.08B↑ | $1.03B↑ | $646.30M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$114.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.41%
Volume
Today's trading volume
1.25M
Recent News
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.
3 Healthcare Stocks with Competitive Advantages
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 10%, nearly mirroring the S&P 500.
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.
Vertex was sole bidder in high-premium Crinetics acquisition
Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.
Biotech IPO Gains Crush AI Listings With Standout 55% Return
(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam